
RAPP Stock Forecast & Price Target
RAPP Analyst Ratings
Bulls say
Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule medications for neurological and psychiatric conditions. The company's lead asset RAP-219, a selective AMPA modulator targeting TARPγ8, is currently in development for focal onset seizures and bipolar mania. Additionally, RAP-219 has a long half-life and potential for durability of response, addressing key concerns for patients and healthcare providers. There is a compelling "pipeline in a product" story for RAP-219, as the overlapping biology between focal onset seizures and bipolar mania indicates a broad commercial opportunity. With multiple positive data points and strong regulatory support, Rapport Therapeutics is well-positioned for success.
Bears say
Rapport Therapeutics is heavily reliant on its single drug RAP-219, which is in the early stages of development. Additionally, the company's pipeline consists mainly of discovery-stage programs, making it highly risky. The company also has a limited geographic presence, operating only in the United States, which could limit its market potential. These factors, along with the uncertainty of drug development and approval, make the outlook for Rapport Therapeutics's stock negative.
This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPP Analyst Forecast & Price Prediction
Start investing in RAPP
Order type
Buy in
Order amount
Est. shares
0 shares